Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...

The Biden administration, through policy and leadership appointments, raised the level of government scrutiny over ...

Reflecting on 20 years of experience working as a scientist in Big Pharma and biotech, Louise Modis, Ph.D., CSO at Amphista ...

Paul Romness claims that ADCs are now as promising as monoclonal antibodies were ten years ago and gives updates on OS Therapies' current pipeline.

Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.